Evidently not, according to a large, Danish, population-based, case–control study.
Evidently not, according to a large, Danish, population-based, case–control study.
Clomiphene, which is structurally related to diethylstilbestrol (DES), has been linked to urogenital anomalies and testicular cancer in males exposed in utero. In addition, hypospadias has been reported in boys born to women exposed to DES in utero.
But this latest study calculated an odds ratio of developing hypospadias after exposure to clomiphene of only 0.48 (95% CI; 0.15–1.54). Restricting exposure to clomiphene to the first trimester and up to 30 days prior to conception did not alter the result substantially.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More